All things considered, our results show little impact of CYP2C19 metabolic phenotypes on early treatment persistence, treatment discontinuation, or switch to another antidepressant in bipolar disorder patients taking sertraline, citalopram, escitalopram, amitriptyline, and clomipramine. Here, CYP2C19 is linked to bipolar disorder.